News Category
SCHOTT Pharma's updated climate targets, validated by the Science Based Targets initiative, introduce a new absolute Scope 3 emissions reduction goal,...
Helus Pharma's completion of enrollment in its pivotal Phase 3 APPROACH trial for HLP003 in major depressive disorder brings the company closer to a p...
VERAXA Biotech AG progresses its VXA-222 bispecific antibody-drug conjugate into the next development stage after completing the discovery phase with ...
Tonix Pharmaceuticals received FDA feedback supporting its adaptive Phase 2 study of TNX-4800, a long-acting antibody for Lyme disease prevention, wit...
VERAXA Biotech's bispecific ADC program VXA-222 hits a key milestone under its OmniAb collaboration, advancing to the next phase of development for pr...
VERAXA Biotech AG appoints Christoph Erkel, Ph.D., as Chief Scientific Officer to lead advancement of its proprietary BiTAC platform technologies for ...
NanoViricides announced a $3.8 million registered direct offering with a single institutional investor, providing capital to advance its lead drug can...
VERAXA Biotech AG announced the appointment of Christoph Erkel as Chief Scientific Officer, leveraging his two decades of antibody therapeutics experi...
VERAXA Biotech AG has received Scientific Advice from Germany's Paul-Ehrlich-Institute supporting the development strategy for its lead BiTAC-TCE prog...
VERAXA Biotech AG (NASDAQ: VRXA) received Scientific Advice from Germany's Paul-Ehrlich-Institute for its BiTAC-TCE platform, providing clarity on dev...
Siegfried appoints Eduardo Montanha as Chief Operating Officer to lead its newly combined Drug Substances and Drug Products operations, reinforcing it...
NextPlat Corp (NASDAQ: NXPL, NXPLW) announced an agreement to acquire an independent pharmacy near Pensacola, Florida, for $1.5 million, expanding its...
Onco-Innovations Limited announced the successful completion of its analytical reference standard program for ONC010, a key step toward clinical readi...
VERAXA Biotech has initiated cell line development for its lead BiTAC T-cell engager program in partnership with ATUM, marking a key step toward IND/C...
The sustained release polymers market is projected to grow from USD 3.8 billion in 2026 to USD 7.8 billion by 2036 at a CAGR of 7.4%, driven by rising...
VERAXA Biotech reported progress in its BiTAC platform and partnering strategy, with a pipeline of four BiTAC-based T-cell engager programs and plans ...
VERAXA Biotech has started cell line development for its lead BiTAC T-cell engager program, leveraging ATUM's Leap-In Transposase technology to advanc...
The article discusses how deal activity in antibody-drug conjugates and T-cell engagers creates value for companies like VERAXA Biotech AG, emphasizin...
Ace Therapeutics announces end-to-end preclinical services for pain therapeutics, including diverse in vivo pain models and a full suite of research c...
Medios AG is closing its Aschaffenburg facility and consolidating patient-specific manufacturing to improve efficiency and counter sustained margin pr...
Helus Pharma reported fiscal 2026 financial results, highlighting over 88% enrollment in its Phase 3 APPROACH trial for HLP003, with topline data expe...
Voyageur Pharmaceuticals has engaged Fluor Corporation to conduct feasibility studies for a domestic iodine extraction facility and an integrated cont...
Knight Therapeutics has repaid the $60 million drawn from its revolving credit facility in June 2025 to finance the acquisition of Paladin, funded by ...
Voyageur Pharmaceuticals is assessing potential U.S. locations for a vertically integrated iodine and barium contrast media plant, aiming to secure do...
Earth Science Tech Inc. has transformed into a diversified holding company with a vertically integrated telehealth and pharmacy ecosystem, emphasizing...
Voyageur Pharmaceuticals has applied for a five-year advanced exploration permit at its Frances Creek barite project, aiming to produce 2,000 tonnes o...
Voyageur Pharmaceuticals closed a $5.0 million non-brokered private placement under the Listed Issuer Financing Exemption to fund FDA licensing for it...
Kairos Pharma announced plans to acquire rights to CL-741, a Phase 1-ready oral c-MET kinase inhibitor, and reported progress in its oncology pipeline...
Quantum BioPharma discussed its lead drug candidate Lucid-MS for multiple sclerosis and its commercial alcohol metabolism product unbuzzd, emphasizing...
Quantum BioPharma's clinical-stage multiple sclerosis program targeting demyelination, coupled with a diversified portfolio spanning therapeutics and ...
Redwood AI Corp. achieves DTC eligibility for its shares, simplifying U.S. trading and enhancing liquidity, while also engaging IBN for a comprehensiv...
Carmed Pharmaceuticals, a Turkey-based company specializing in standardized carvacrol-based formulations, is featured in CityBiz as it expands into th...
Sino Biological's new XPressMAX™ Cell-Free Protein Synthesis Kit enables ultra-fast protein and antibody synthesis in 3 hours, supporting AI-driven hi...
NanoViricides reported progress on NV-387, its broad-spectrum antiviral candidate, including regulatory approval for Phase II trials in the DRC for MP...
NanoViricides announced a $2 million registered direct offering with a single institutional investor to advance its broad-spectrum antiviral drug NV-3...
Lantern Pharma raised $4.4 million in a registered direct offering, with potential additional proceeds from warrants, to advance its precision oncolog...
Tonix Pharmaceuticals management will present at the RBC Capital Markets Global Healthcare Conference and A.G.P.'s Virtual Healthcare Conference in Ma...
Lantern Pharma announces the expansion of its predictBBB platform into a Large Quantitative Model, providing researchers with a real-time molecular in...
LIXTE Biotechnology is advancing LB-100, a first-in-class PP2A inhibitor designed to boost the effectiveness of existing cancer treatments, with ongoi...
Soligenix leverages its synthetic hypericin platform to target both cutaneous T-cell lymphoma and psoriasis, demonstrating how platform-based drug dev...
PolyPeptide Group AG's shareholders approved all board proposals, including re-election of directors and compensation packages, affirming confidence i...
LIXTE Biotechnology Holdings filed its 2025 Form 10-K, detailing leadership changes, clinical advancement of LB-100, acquisition of Liora Technologies...
LIXTE Biotechnology holds the only clinical-stage PP2A inhibitor, LB-100, which enhances cancer cell sensitivity to therapies and disrupts repair syst...
Lonza nominates former Eli Lilly executive Stephen Fry to its Board, aiming to strengthen its performance culture and organizational transformation wi...
Voyageur Pharmaceuticals is progressing its vertically integrated barium and iodine contrast media projects, targeting FDA approval by mid-2027 and co...
Soligenix receives positive EMA opinion for orphan drug designation of dusquetide in Behcet's disease, unlocking development incentives and validating...
Quoin Pharmaceuticals' NETHERTON NOW campaign has achieved 2 million video views and 24 million impressions, highlighting the urgent need for treatmen...
Oncotelic Therapeutics was featured in a BioMedWire editorial discussing how pharmaceutical companies are prioritizing late-stage, de-risked assets in...
